Cita APA (7a ed.)

Preiss, D., Herrington, W., & Haynes, R. (2022). Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: The EMPA-KIDNEY trial. American Heart Association.

Cita Chicago Style (17a ed.)

Preiss, D., W. Herrington, y R. Haynes. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.

Cita MLA (9a ed.)

Preiss, D., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.